Abstracts tagged "Genetics and giant cell arteritis"

Abstract Number: 3140 • 2015 ACR/ARHP Annual Meeting
A Meta-Immunochip Analysis Suggests IL12B As a Common Susceptibility Factor for Large-Vessel Vasculitides
Francisco David Carmona¹, Patrick Coit², Güher Saruhan-Direskeneli³, Maria C. Cid⁴, Roser Solans⁵, Santos Castañeda⁶, Augusto Vaglio (on behalf of the Italian GCA Study Group)⁷, Haner Direskeneli (on behalf of the Turkish Takayasu Study Group)⁸, Peter A. Merkel⁹, Carlo Salvarani¹⁰, Miguel A. Gonzalez-Gay¹¹, Javier Martín¹², Amr H. Sawalha² and Spanish GCA consortium, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Autoimmune and Systemic Diseases, Hospital Clínic. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain, ⁶Rheumatology, H.U. La Princesa, Madrid, Spain, ⁷Medicina Clinica e Nefrologia, Università di Parma, Parma, Italy, ⁸Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁰Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ¹¹Reumatologia, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ¹²Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Large-vessel vasculitides (LVV) comprise giant cell arteritis (GCA) and Takayasu arteritis (TAK). They are characterized by self-sustaining inflammatory damage of the wall of large-sized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].